IL2 and ocular melanoma: Additionally, at day 90, GEMCOVAC-OM showed significantly higher TNF+CD4+ T cells and IL-2+CD8+ T cells compared with GEMCOVAC-19 (phase 2) and higher TNF+CD4+, IL-2+CD4+ and IL-2+CD8+ T cells compared with ChAdOx1 nCoV-19 (phase 3), indicating a durable T cell protection with BA.1-specific vaccine.